Mayra Tisminetzky to Angiotensin Receptor Antagonists
This is a "connection" page, showing publications Mayra Tisminetzky has written about Angiotensin Receptor Antagonists.
Connection Strength
0.894
-
Tisminetzky M, Joffe S, McManus DD, Darling C, Gore JM, Yarzebski J, Lessard D, Goldberg RJ. Decade-long trends in the characteristics, management and hospital outcomes of diabetic patients with ST-segment elevation myocardial infarction. Diab Vasc Dis Res. 2014 May; 11(3):182-9.
Score: 0.436
-
Tisminetzky M, Gurwitz JH, Tabada G, Reynolds K, Fortmann SP, Garcia E, Pham T, Goldberg R, Go AS. Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity. Am J Med. 2022 12; 135(12):1468-1477.
Score: 0.196
-
Gurwitz JH, Magid DJ, Smith DH, Tabada GH, Sung SH, Allen LA, McManus DD, Goldberg RJ, Tisminetzky M, Go AS. Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease. J Am Geriatr Soc. 2017 Dec; 65(12):2610-2618.
Score: 0.139
-
Awad HH, Tisminetzky M, Metry D, McManus D, Yarzebski J, Gore JM, Goldberg RJ. Magnitude, treatment, and impact of diabetes mellitus in patients hospitalized with non-ST segment elevation myocardial infarction: A community-based study. Diab Vasc Dis Res. 2016 Jan; 13(1):13-20.
Score: 0.122